Rhenman & Partners Asset Management AB Cuts Holdings in Dianthus Therapeutics, Inc. $DNTH

Rhenman & Partners Asset Management AB trimmed its holdings in shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) by 43.2% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 98,627 shares of the company’s stock after selling 75,000 shares during the period. Rhenman & Partners Asset Management AB’s holdings in Dianthus Therapeutics were worth $4,064,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in Dianthus Therapeutics by 4.2% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,334 shares of the company’s stock valued at $280,000 after purchasing an additional 618 shares during the last quarter. Deutsche Bank AG boosted its stake in Dianthus Therapeutics by 9.3% during the 4th quarter. Deutsche Bank AG now owns 15,831 shares of the company’s stock valued at $652,000 after purchasing an additional 1,343 shares during the last quarter. Raymond James Financial Inc. purchased a new stake in Dianthus Therapeutics during the 2nd quarter valued at $27,000. Russell Investments Group Ltd. purchased a new stake in Dianthus Therapeutics during the 3rd quarter valued at $64,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank purchased a new stake in Dianthus Therapeutics during the 4th quarter valued at $135,000. 47.53% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, EVP Ryan Savitz sold 114,367 shares of the firm’s stock in a transaction on Tuesday, March 31st. The stock was sold at an average price of $83.00, for a total value of $9,492,461.00. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Simrat Randhawa sold 26,530 shares of the firm’s stock in a transaction on Monday, June 1st. The stock was sold at an average price of $90.62, for a total value of $2,404,148.60. Following the completion of the transaction, the executive vice president directly owned 4,000 shares in the company, valued at approximately $362,480. This represents a 86.90% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 149,121 shares of company stock worth $12,635,454. 3.02% of the stock is owned by insiders.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on the company. Raymond James Financial restated a “strong-buy” rating on shares of Dianthus Therapeutics in a research note on Wednesday. Truist Financial raised their price target on Dianthus Therapeutics from $63.00 to $110.00 and gave the stock a “buy” rating in a research note on Monday, March 9th. Wells Fargo & Company assumed coverage on Dianthus Therapeutics in a research note on Thursday, March 19th. They issued an “overweight” rating and a $135.00 price target on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Dianthus Therapeutics in a research note on Monday, April 20th. Finally, Guggenheim restated a “buy” rating on shares of Dianthus Therapeutics in a research note on Wednesday. One analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Dianthus Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $117.82.

Dianthus Therapeutics Price Performance

DNTH stock opened at $82.07 on Friday. The company has a market cap of $4.49 billion, a P/E ratio of -19.87 and a beta of 1.18. Dianthus Therapeutics, Inc. has a 1 year low of $16.64 and a 1 year high of $96.50. The stock’s fifty day moving average price is $87.10 and its 200-day moving average price is $65.07.

Dianthus Therapeutics (NASDAQ:DNTH) last released its quarterly earnings results on Tuesday, May 5th. The company reported ($0.85) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.07) by $0.22. The firm had revenue of $0.46 million for the quarter, compared to the consensus estimate of $0.40 million. Dianthus Therapeutics had a negative return on equity of 27.30% and a negative net margin of 12,998.50%. As a group, analysts expect that Dianthus Therapeutics, Inc. will post -3.82 earnings per share for the current year.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.